araag2/HINT huggingface dataset:
Clinical trial NCT00550043 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: incb018424, placebo
SMILES: N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Established diagnosis of rheumatoid arthritis

          2. Patients receiving methotrexate must be treated with for at least 6 months and
             receiving a stable weekly dose between 10 and 25 mg for at least 8 consecutive weeks
             prior to study entry.

        Exclusion Criteria:

          1. Patients who have taken the following drugs within the timeframe below:

               -  Leflunomide, infliximab, etanercept, adalimumab, abatacept, or other biological
                  therapies (except rituximab) - Within 12 weeks prior to the first dose of study
                  medication;

               -  Rituximab - Within 12 months prior to the first dose of study medication;

               -  Disease-modifying anti-rheumatic drugs (DMARDs) or other anti-rheumatic therapies
                  not specified above including but not limited to: gold, penicillamine, dapsone,
                  azathioprine, 6-mercaptopurine, chlorambucil, cyclophosphamide, cyclosporin,
                  mycophenolate mofetil - Within 12 weeks prior to the first dose of study
                  medication;

          2. Treatment with any investigational medication within 12 weeks prior to the first dose
             of study medication.
Clinical trial NCT00303524 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: goserelin acetate, goserelin acetate
SMILES: CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Pre-menopausal women aged 20 years or over with histological/cytologically-confirmed
             ER +ve breast cancer who have undergone radical surgery and WHO performance status 0,1
             or 2.

        Exclusion Criteria:

          -  Evidence of metastatic disease, previous bilateral oophorectomy or radiotherapy to the
             ovaries, previous chemotherapy, breast surgery completed over 12 weeks before starting
             trial treatment, previous neo-adjuvant/adjuvant hormonal breast cancer therapy
Clinical trial NCT00754702 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: vinorelbine, lapatinib
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically- or cytologically- confirmed metastatic breast adenocarcinoma

          -  Age 18-75 years

          -  HER2 status positive according to the local institution reported grade 3+ staining
             intensity (on a scale of 0 to 3) by means of immunohistochemical analysis or grade 2+
             staining intensity by means of immunohistochemical analysis with gene amplification on
             fluorescence in situ hybridization

          -  Previous therapies had to include, regimens containing an anthracycline and a taxane

          -  Previous treatment with trastuzumab, alone or in combination with chemotherapy for
             locally advanced or metastatic disease, is required

          -  Measurable disease as defined by the presence of at least one measurable lesion
             (except bone metastases, ascites or pleural effusions)

          -  Performance status (WHO) 0-2

          -  Adequate liver (serum bilirubin <1.5 times the upper normal limit; AST and ALT <2.5
             times the upper normal limit in the absence of demonstrable liver metastases, or <5
             times the upper normal limit in the presence of liver metastases); adequate renal
             function (serum creatinine <1.5 times the upper normal limit); and bone marrow
             (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L) function

          -  No radiation of measurable disease (except brain metastases)

          -  No progressive brain metastases according to clinical or radiological criteria

          -  No brain metastases without prior radiation therapy

          -  Written informed consent

        Exclusion Criteria:

          -  Patient unable to take oral medication

          -  Active infection

          -  History of significant cardiac disease (unstable angina, congestive heart failure,
             myocardial infarction within the previous 6 months, ventricular arrhythmias)

          -  Other invasive malignancy except nonmelanoma skin cancer

          -  Psychiatric illness or social situation that would preclude study compliance

          -  Pregnant or lactating women
Clinical trial NCT01666691 (phase 2, status: completed)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: beloranib, placebo
SMILES: CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C1=CC=C(OCCN(C)C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Obese volunteers weighing ≥ 50 kg

          -  BMI ≥ 30 and ≤ 50 kg/m2

          -  Stable body weight during the past 2 months

          -  Type 2 diabetes mellitus is allowed

        Exclusion Criteria:

          -  Use of weight loss agents in the past month

          -  Current, clinically significant eating disorder

          -  Type 1 diabetes mellitus
Clinical trial NCT00057031 (phase 2, status: unknown status)
Conditions: myelodysplastic syndrome
ICD codes: D46.9, D46.C, D46.Z
Drugs: dn-101 (calcitriol)
SMILES: C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
Eligibility criteria:

        -  Diagnosis of low or intermediate-1 risk MDS

          -  Dependent on monthly blood transfusions

          -  No cancer within the last 5 years (cured skin cancer is allowed)

          -  No heart attack or stroke within the last 6 months

          -  No kidney stones within the last 5 years
Clinical trial NCT01077297 (phase 2, status: terminated)
Conditions: pulmonary arterial hypertension
ICD codes: I27.21
Drugs: tezosentan
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=NC=C(C=C2)C(C)C)N=C(N=C1OCCO)C1=CC(=NC=C1)C1=NNN=N1
Reason stopped: 
    due to slow recruitment, the study was prematurely discontinued
  
Eligibility criteria:

        Inclusion Criteria:

          1. Signed informed consent

          2. Male and female patients 18 years of age or older

          3. Patients with PAH according to one of the following subgroups of the Venice
             Classification Group 1:

               -  Idiopathic (iPAH), or

               -  Familial/heritable (FPAH), or

               -  Associated (APAH) with collagen vascular disease

          4. Modified NYHA functional class II-III

          5. Documented hemodynamic diagnosis of PAH by right heart catheterization at Baseline:

               -  Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg and

               -  Resting mean PVR ≥ 240 dyn•s•cm-5 and

               -  Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg

        Exclusion Criteria:

          1. Patients with PAH in Venice Classification Groups 2-5, and PAH Group 1 subgroups not
             covered by inclusion criterion no. 3

          2. Hypotensive patients (systemic systolic blood pressure < 100 mmHg)

          3. Patients with body weight < 50 kg (110 lbs)

          4. Patients with moderate or severe hepatic impairment (Child-Pugh B and C)

          5. Patients with clinically significant chronic renal insufficiency (serum creatinine >
             2.5mg/dL / 221µmol/L)

          6. Patients who have received any endothelin receptor antagonist (ERA) and/or any
             phosphodiesterase-5 (PDE-5) inhibitor within 28 days of Baseline

          7. Patients who have received prostacyclin (epoprostenol) or prostacyclin analogs (e.g.,
             treprostinil, iloprost) within 28 days of Baseline

          8. Patients who have received any investigational drugs within 28 days of Baseline

          9. Patients who have received cyclosporine A or tacrolimus within 28 days of Baseline

         10. Psychotic, addictive or other disorder limiting the ability to provide informed
             consent or to comply with the study

         11. Life expectancy less than 12 months

         12. Females who are lactating or pregnant or females who are not using a reliable method
             of birth control (failure rate less than 1% per year) during the study and for at
             least one month after study drug intake

         13. Known hypersensitivity to any of the excipients of the drug formulation

         14. Patients with positive response to vasoreactivity test
Clinical trial NCT00135525 (phase 2, status: completed)
Conditions: anxiety disorder, anxiety disorders
ICD codes: F41.1, F41.9, F40.9, F43.22, F41.0, F93.0, F12.980, F41.1, F41.9, F40.9, F43.22, F41.0, F93.0, F12.980
Drugs: paroxetine, placebo
SMILES: FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Generalized Anxiety Disorder (GAD) according to Diagnostic and
             Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria.

          -  Must give a written informed consent. But if the patient is under 20, both the patient
             himself/herself and his/her proxy consenter must give written informed consent.

        Exclusion Criteria:

          -  Have the following conditions currently or diagnosed in the past 24 weeks:

        Major Depressive Episode, Panic Disorder Without Agoraphobia, Panic Disorder With
        Agoraphobia, Social phobia/social anxiety disorder (SAD), Agoraphobia Without History of
        Panic Disorder, Posttraumatic Stress Disorder, Obsessive Compulsive Disorder, Anorexia
        Nervosa, Bulimia Nervosa, Dysthymic disorder

          -  Current or history of schizophrenia, bipolar disorder or cyclothymic disorder.

          -  Psychotherapy or cognitive behavioral therapy other than supportive psychotherapy.

          -  Current or history of substance abuse (alcohol or drugs) or substance in past 24
             weeks.

          -  Taken St. John's Wort in past 4 weeks.

          -  Had electroconvulsive therapy (ECT) in past 12 weeks.

          -  Had psychotherapy or cognitive behavioral therapy other than supportive psychotherapy
             within 24 weeks.

          -  Women who are pregnant or lactating, who may be pregnant, or who plan for pregnancy by
             30 days after the completion of final dose.

          -  Pose a suicidal threat or have attempted suicide in past 24 weeks.

          -  History of convulsive disorder (epilepsy, etc.).

          -  Significant unstable medical illness.

          -  Current or history of glaucoma.

          -  History or complication of cancer or malignant tumor.

          -  History of hypersensitivity to paroxetine.
Clinical trial NCT01051817 (phase 2, status: completed)
Conditions: relapsing-remitting multiple sclerosis, rrms
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: ain457, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        -

        Exclusion Criteria:

        -
Clinical trial NCT01517373 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo, pf-04937319 10 mg, pf-04937319 50 mg, pf-04937319 100 mg, glimepiride
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18-70 yrs, male and females, with T2DM, on metformin alone or in combination with
             1 other oral agent

        Exclusion Criteria:

          -  Subjects with recent cardiovascular events, those with evidence of diabetic
             complications
Clinical trial NCT01318109 (phase 2/phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: alogliptin and metformin, alogliptin and metformin, metformin
SMILES: CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Had been taking metformin at a stable dose regimen (500 mg/day twice daily after meal
             or 750 mg/day three times daily after meal) for at least 12 weeks prior to the
             initiation of the treatment period (Week 0).

          2. Had an glycosylated hemoglobin (HbA1c) of 6.5% or more and below 10.0% at 8 weeks
             after the initiation of the observation period (Week -4).

          3. Had an HbA1c difference between 4 weeks after the initiation of the observation period
             (Week -8) and 8 weeks after the initiation of the observation period (Week -4) being
             within 10.0%* of the value at 4 weeks after the initiation of the observation period
             (Week -8) (*rounded off to the first decimal place).

          4. Was receiving specific diet and exercise (if any) therapies during the observation
             period.

        Exclusion Criteria:

          1. Had taken other diabetic medications than metformin within 12 weeks before the
             initiation of the treatment period (Week 0).

          2. With a history or symptoms of lactic acidosis.
Clinical trial NCT01458197 (phase 2, status: completed)
Conditions: overactive bladder
ICD codes: N32.81
Drugs: tarafenacin 0.2 mg, placebo, tarafenacin 0.4 mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        < Inclusion Criteria>

          1. Patient of either sex aged 20 to 80 years (both inclusive);

          2. Patients suffering from Overactive Bladder. based on cardinal symptoms (urgency,
             nocturia, frequency with or without urge incontinence) for at least 6 months prior to
             inclusion;

          3. Patients who document the following symptoms in a 3-day diary card during the 14 day
             placebo run-in period

               -  An average of ≥8 micturitions/24 hours;

               -  Greater than or equal to three incontinence episodes

               -  A total of ≥3 urgency episodes.

        <Exclusion Criteria>

          1. Patients with Clinically significant bladder outlet obstruction

          2. Patients with predominant stress incontinence (>2 episode/week)

          3. Patients with significant urogenital disease such as recurrent urinary tract infection
             (more than 2/6 months), bladder calculi, interstitial cystitis, urothelial tumours,
             hysterectomy or prostatectomy in the previous six months;

          4. Females diagnosed with bladder cancer

          5. Males diagnosed with bladder cancer

          6. Patients with obstructive disease of the gastrointestinal tract, intestinal
             inflammatory disease, severe ulcerative colitis, inflammatory bowel disease, toxic
             megacolon, intestinal atony or paralytic ileum

          7. Patients with acute Noehyeolgwangye disease, significant Cardiovascular Disease
             (arrhythmias, unstable angina pectoris, myocardial infarct, or are using a pacemaker),
             significant Orthostatic hypotension in the previous six months

          8. Patients diagnosed with closed angle glaucoma or shallowness of the anterior chamber

          9. Patients with any contraindication to antimuscarinic drugs
Clinical trial NCT01822249 (phase 2, status: completed)
Conditions: rett syndrome
ICD codes: F84.2
Drugs: epi-743, placebo
SMILES: CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Rett syndrome with disease stage 1-2

          -  Abnormality of at least two disease biomarker levels

          -  Confirmed MeCP2 mutation

          -  Patient or patient's guardian able to consent and comply with protocol requirements

          -  Abstention from use of Coenzyme Q10, vitamin E and Idebenone two weeks prior to
             enrollment into the study

        Exclusion Criteria:

          -  Any condition, which in the opinion of the investigator could compromise the subject's
             safety or adherence to treatment with EPI-743.

          -  Clinically significant allergy or hypersensitivity to EPI-743 or to any of the
             excipients of with EPI-743 (eg., sesame oil).

          -  Clinically significant allergy or hypersensitivity to Vitamin E

          -  Lack of confirmation of MeCP2 mutation

          -  Clinical history of bleeding or abnormal baseline PT/PTT

          -  Diagnosis of any other concurrent inborn error of metabolism

          -  Hepatic insufficiency with LFTs greater than 3 times upper limit of normal

          -  Renal insufficiency requiring dialysis

          -  End stage cardiac failure

          -  Fat malabsorption syndromes precluding drug absorption
Clinical trial NCT00500760 (phase 2, status: completed)
Conditions: head and neck cancer, squamous cell carcinoma
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11, C44.520, C44.92, C44.02, C44.321, C44.521, C44.82, C44.42
Drugs: cisplatin, panitumumab
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of Stage III or IVa-b (M0) squamous cell carcinoma of the oral
             cavity, oropharynx, hypopharynx or larynx

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (you must be
             well enough to receive chemoradiation therapy)

          -  You must be at least 18 years of age

          -  Your test results must show that your kidneys, liver and blood cells are working
             adequately and that, if you are female, you are not pregnant

          -  You must have measurable disease

        Exclusion Criteria:

          -  Cancer of the nasopharynx, sinus, salivary gland or skin

          -  History of another cancer (other than head and neck) unless treated with curative
             intent and with no evidence of disease for more than 3 years, with the exception of
             non-melanoma skin cancer or in situ cervical cancer

          -  Previous treatment with anti-endothelial growth factor receptor (EGFr) antibody
             therapy or EGFr inhibitors

          -  Previous treatment for head and neck cancer, with chemotherapy, surgery (except nodal
             sampling or biopsy) or radiotherapy

          -  Clinically significant cardiovascular disease (including myocardial infarction,
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac
             arrhythmia) within one year before you join the study

          -  Chronic obstructive pulmonary disease (pneumonia or respiratory decompensation)
             resulting in hospitalization within 6 months of study screening

          -  History or evidence of interstitial lung disease (e.g. pneumonitis or pulmonary
             fibrosis)

          -  Major surgery within 28 days of screening
Clinical trial NCT00522925 (phase 2, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: ps433540, placebo, ps433540
SMILES: CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C(COCC)=C1)C1=CC=CC=C1S(=O)(=O)NC1=NOC(C)=C1C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C(COCC)=C1)C1=CC=CC=C1S(=O)(=O)NC1=NOC(C)=C1C
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females 30 - 80 years

          -  Mean seated Systolic Blood Pressure (SBP) ≥ 150 - ≤ 179 mmHg and mean seated DBP < 110
             mmHg at two consecutive qualifying visits. The mean difference in SBP between the two
             consecutive qualifying visits must be ≤ 10 mmHg.

          -  Mean daytime (8AM - 4PM) ambulatory SBP must be between ≥ 140 - ≤ 179 mmHg and mean
             daytime (8AM - 4PM) Diastolic Blood Pressure (DBP) ≤ 110 mmHg

          -  Subjects must have a usual daytime schedule. Night shift workers are excluded from
             participation.

          -  Women of child-bearing potential (WOCBP) and male subjects must use two reliable forms
             of contraception if sexually active. Alternatively, female subjects must be
             postmenopausal (for at least 1 year)

        Exclusion Criteria:

          -  Subjects with serious disorders which may limit the ability to evaluate the efficacy
             or safety of PS433540, including cardiovascular, renal (including the absence of one
             kidney), pulmonary, hepatic, gastrointestinal (including clinically significant
             malabsorption), endocrine/metabolic, hematologic/oncologic (including an active
             malignancy other than basal cell carcinoma), neurologic and psychiatric diseases.

          -  Subjects with a history of myocardial infarction, angina, coronary angioplasty, bypass
             surgery or New York Heart Association (NYHA) class II-IV heart failure within the last
             6 months.

          -  Subjects with a history of cerebrovascular accident or transient ischemic attack
             within the last 1 year.

          -  Subjects with diabetes mellitus (type I and type II).